Litigation Details for Anesta AG v. Mylan Pharmaceuticals Inc. (D. Del. 2008)

Anesta AG v. Mylan Pharmaceuticals Inc. (D. Del. 2008)

Docket	1:08-cv-00889	Date Filed	2008-11-25
Court	District Court, D. Delaware	Date Terminated	2014-09-24
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	Defendant	Referred To
Parties	TEVA PHARMACEUTICAL INDUSTRIES LTD.
Patents	7,387,793; 7,544,372
Attorneys	Olivia M. Kim
Firms	Phillips, McLaughlin & Hall, P.A.
Link to Docket	External link to docket

Details for Anesta AG v. Mylan Pharmaceuticals Inc. (D. Del. 2008)

Date Filed	Document No.	Description	Snippet	Link To Document
2008-11-25				External link to document

Litigation Summary and Analysis: Anesta AG v. Mylan Pharmaceuticals Inc. (D. Del. 1:08-cv-00889)

Last updated: June 24, 2026

Anesta AG’s case against Mylan Pharmaceuticals Inc. in D. Del. (1:08-cv-00889) is a patent infringement dispute tied to an ANDA/generic entry theory under the Hatch-Waxman framework. The record is framed as a Paragraph IV-type challenge where the patentee alleges infringement of one or more Orange Book-listed patents by Mylan’s proposed generic product, while Mylan contests validity and/or non-infringement and raises typical statutory defenses.

What is the case background for Anesta AG v. Mylan Pharmaceuticals Inc. 1:08-cv-00889?

The docket number identifies a federal patent case filed in the U.S. District Court for the District of Delaware in 2008. The parties are:

• Plaintiff: Anesta AG
• Defendant: Mylan Pharmaceuticals Inc.
• Case: 1:08-cv-00889 (D. Del.)

Which drug and patents are at issue in Anesta AG v. Mylan Pharmaceuticals Inc.?

The provided case citation does not include the asserted product, active ingredient, or patent numbers. Without the patent list (Orange Book reference drug and patent identifiers) and without the ANDA details, a complete litigation analysis cannot be constructed to the standard required for freedom-to-operate, licensing, or litigation strategy decisions.

What procedural posture does the case follow?

At a high level, Hatch-Waxman patent suits typically follow this sequence:

1. Patentee sues within the statutory window after receipt of notice of paragraph IV certification (or after filing of an ANDA that includes a paragraph IV certification).
2. Parties litigate infringement, invalidity, and statutory defenses.
3. The court enters schedule and claim constructions, then resolves dispositive issues or issues a merits judgment.
4. Settlement may occur with a covenant not to sue, delayed launch, or other consideration.

The case caption provided indicates an infringement dispute, but the specific procedural steps, dates, and outcomes are not included in the prompt.

Which claims did Anesta AG assert, and what did Mylan argue in response?

What infringement theory did Anesta AG use?

In ANDA cases, plaintiffs typically assert:

• Direct infringement based on manufacture, use, sale, offer for sale, or importation of the ANDA product
• Potentially induced infringement or contributory infringement theories depending on the record
• Infringement of asserted claims of Orange Book patents covering drug substance, formulation, method of use, or manufacturing

How did Mylan typically defend in Hatch-Waxman actions?

Defendants typically argue:

• No infringement (non-read) of asserted claims
• Invalidity (anticipation, obviousness, lack of enablement/adequate written description, indefiniteness, or statutory ineligibility if applicable)
• Statutory defenses tied to the ANDA certification pathway
• Non-infringement based on process or compositional differences

The prompt does not provide the asserted claims, claim construction results, or the invalidity theories used in this specific case, so a claim-by-claim assessment is not possible.

What were the key events in the 1:08-cv-00889 timeline?

A litigation timeline requires docket-level events such as:

• Complaint filing date
• Service/answer dates
• Motions to dismiss or for summary judgment
• Claim construction order dates
• Final judgment or settlement dates
• Any PTAB activity stay orders (if any)
• Execution of settlement terms (if any)
• Any appeal activity

No such dates or docket events are included in the user-provided input, preventing an accurate timeline.

How strong was Anesta AG’s patent estate versus Mylan’s generic risk?

What patent categories were likely targeted?

In generic challenge cases, plaintiffs’ estates frequently include patents in one or more categories:

• Drug substance
• Composition/formulation
• Method of use
• Manufacturing/process
• Crystalline forms or polymorphs
• Pediatric exclusivity-related strategy (rarely asserted as patents but may drive timing)

However, without the actual asserted patent numbers and claim scope, this can’t be tied to the real estate in this case.

What validity and infringement issues usually decide these cases?

Typical decisional pivots include:

• Whether the generic product (or its proposed label) reads on the asserted claims
• Whether the asserted claims are invalid for obviousness/anticipation
• Whether written description and enablement support the claim breadth
• Whether claim construction narrows or broadens the asserted scope

A merits-based strength analysis requires the court’s holdings, not just general patterns.

Was there a Paragraph IV ANDA settlement or a court judgment in this matter?

A complete litigation analysis for high-stakes decisions requires one of:

• A final merits judgment (with findings on infringement and validity)
• A consent judgment, stipulated dismissal with prejudice
• A settlement agreement and associated consent order or stay of action pending launch dates
• A dismissal for lack of jurisdiction, procedural defect, or mootness

The prompt provides no settlement/judgment disposition, so the exclusivity and generic launch implications cannot be stated.

How does this lawsuit affect market entry timelines for Mylan and competing generics?

What generic entry risks would exist absent a settlement?

If the case proceeded to final judgment in the patentee’s favor on infringement and validity, Mylan’s ANDA typically faces:

• Injunction preventing launch until patent expiry
• Potential design-around pressure if only certain claims were infringed
• Additional barriers if multiple patents are listed and staggered

What changes if the case settled?

Settlement outcomes typically convert patent risk into contractual risk:

• Launch delay commitments
• Royalty or per-unit payment
• Carve-outs for different strengths, dosage forms, or modified formulations
• Dismissal with specific end dates tied to patent expiration or earlier milestones

No settlement terms or disposition are provided, so the real-world launch-risk profile for Mylan in 1:08-cv-00889 cannot be quantified.

What is the Orange Book status linked to Anesta AG’s asserted patents?

To map Orange Book status, the analysis must have:

• Reference listed drug (RLD)
• All Orange Book patents tied to that RLD
• Which patents were asserted in this case
• Their expiration dates and exclusivity periods (including pediatric exclusivity if applicable)

The prompt does not supply the RLD or asserted patent list, so Orange Book status cannot be produced.

How does Anesta AG v. Mylan Pharmaceuticals Inc. compare with other similar Hatch-Waxman suits in 2008?

A meaningful comparison needs:

• The same court and judge (or consolidated track)
• Similar patent categories (formulation vs method of use)
• Comparable claim construction outcomes
• Whether courts in that period tended to favor patentee or generic on obviousness/infringement

The prompt provides only the case identifier, not the jurisprudential outcome or judicial reasoning, so comparison would be speculative.

Key Takeaways

• The case identifier indicates a D. Del. Hatch-Waxman patent dispute between Anesta AG and Mylan Pharmaceuticals Inc. filed in 2008 (1:08-cv-00889).
• A litigation-grade summary and analysis requires the asserted patents, drug/RLD, docket outcomes, and settlement or judgment disposition, none of which are included in the provided input.
• Without those facts, no accurate statement can be made on infringement findings, validity determinations, or launch/timing consequences for Mylan or other ANDA filers.

FAQs

1. What patents were asserted in Anesta AG v. Mylan Pharmaceuticals Inc. (1:08-cv-00889)?
2. Did the court construe any key claim terms in 1:08-cv-00889, and what was the outcome?
3. Was there a settlement or consent judgment that affected Mylan’s ANDA launch date?
4. Which Orange Book patents for the relevant RLD were implicated by the litigation?
5. Did any appeal or related PTAB proceedings affect the timeline or scope of 1:08-cv-00889?

References

1. U.S. District Court for the District of Delaware. Anesta AG v. Mylan Pharmaceuticals Inc., No. 1:08-cv-00889. (Docket citation as provided by user).